Sirolimus Use in Angioplasty for Vascular Access Extension
common.study.values.description
“Sirolimus Use in Angioplasty for Vascular Access Extension”
Dialysis patients presenting for angioplasty intervention for graft failure will be randomized to receive either Sirolimus or not receive Sirolimus (standard of care) to assess the time from primary failure or angioplasty intervention to second or next angioplasty intervention or graft failure.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-yes
common.study.methods.is-healthy-yes
Drug - Sirolimus
3 mg po od loading dose for two days, then 2 mg po od for thirty days
participant.views.study.view.additional
participant.views.study.view.scientific-title
A Randomized Open Label Trial of Oral Sirolimus for Decrease of Stenosis in Arteriovenous Fistula in Hemo-dialysis Patients When Compared With Standard Therapy
common.study.values.clinical-trial-id
NCT01595841
participant.views.study.view.id
mbk8xd
